International Workshop on HIV Pediatrics 2020

In the past decade, there has been impressive success in the prevention of mother-to-child HIV transmission. However, we have not eliminated the problem of pediatric HIV infection, and much work remains to be done. Research in pediatric, adolescent, and maternal HIV infections is often a neglected area at major scientific HIV conferences, yet it is critical to achieving an AIDS-free generation.

While we have highly effective interventions to prevent HIV transmission, implementation has been incomplete. In 2015, 1.8 million children were living with HIV and 150,000 were newly infected with the disease worldwide. Even with the continued scale-up of preventive services, it is estimated that 2 million children will need antiretroviral treatment (ART) in 2020. Unfortunately, children are substantially less likely than adults to be diagnosed, engaged in care, and to access life-saving ART.

The treatment of pediatric HIV infection, particularly of infants and young children, remains complex and problematic. Rapid growth and organ system maturation, as well as emotional and cognitive changes that occur across the developmental spectrum from infancy through adolescence, complicate drug development, and administration. Adherence outcomes in children have been less than robust and mental health and behavioral issues are emerging as critical to understand and address in order to ensure the success of long-term treatment. Additionally, while fewer infected children are being born, there are increasing concerns about the long-term impact of in utero and post-natal exposures to antiretroviral drugs for those children who escape HIV. Currently, an estimated 20% of all infants born in sub-Saharan Africa are exposed to HIV and antiretrovirals during pregnancy and the post-natal period.

Young people account for half of all new cases of HIV infection worldwide, with adolescent girls and young women disproportionately affected. In sub-Saharan Africa in 2015, three out of four newly infected adolescents aged 15–19 years were girls. Adolescents living with HIV have been a particularly difficult group to reach. HIV was the leading cause of death among adolescents living in Africa and the second-leading cause of death in adolescents globally. The uptake of HIV testing among adolescents has remained low. Programs struggle to reach and retain adolescents in care and adherence to treatment has special challenges.

The pediatric HIV cure agenda is an important emerging area of research. Early infant diagnosis is increasingly available globally, enabling the earlier identification of infection and provides new exciting opportunities to study acute infection in children and promising cure strategies. The HIV Pediatrics Workshop is the only meeting entirely devoted to research in the prevention and treatment of HIV infections in infants, children, and adolescents, making it the premier forum for the world’s leading researchers.

General Information 

Practical Information 

The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.

We are proud to present the members of the committee:

• Moherndran Archary, MBChB, DOH, FCPaeds, University of KwaZulu Natal, South Africa

• Jason Brophy, MD - Children's Hospital of Eastern Ontario, Canada

• Ellen Chadwick, MD - Childrens Memorial Hospital, United States

• Tsungai Chipato, MBChB - University of Zimbabwe College of Health Sciences, Zimbabwe

• Polly Clayden - HIV i-Base, United Kingdom

• Anita De Rossi, PhD - AIDS Reference Center, Italy

• Marinella Della Negra, MD - Hopital Emilio Ribas, Brazil

• Brian Eley, MD - Red Cross Children's Hospital, Department of Pediatrics, South Africa

• Albert Faye, PhD - Denis Diderot University, Paris, France

• Rashida Ferrand, MBBS, MRCP, MSc, DRM&H - London School of Hygiene & Tropical Medicine, United Kingdom

• Tessa Goetghebuer, MD - Hôpital St Pierre, Belgium

• Ali Judd, PhD, London School of Hygiene and Tropical Medicine, United Kingdom

• Valériane Leroy, MD - Inserm, Paris, France

• Chewe Luo, MD, PhD - UNICEF, United States

• Dorothy Mbori-Ngacha, MBChB, MMed, MPH - United Nations Children's Fund, South Africa

• Sharon Nachman, MD - SUNY Health Science Center Stony Brook, United States

• Paul Palumbo, MD - Dartmouth-Hitchcock Medical Center, United States

• Martina Penazzato, MD, DTMH, MSc, PhD - WHO, United Kingdom

• Jorge Pinto, MD, DSc - School of Medicine, Federal University of Minas Gerais, Brasil

• Natella Rakhmanina, MD, PhD, FAAP, AAHIV - Children's National Medical Center, United States

• Theodore Ruel, MD - University of California, San Francisco, United States

• George Siberry, MD, PhD - National Institute of Health, United States

• Lynda Stranix-Chibanda, MBChB, MMED - University of Zimbabwe, Zimbabwe

• Tavitiya Sudjaritruk, MD, ScM, PhD - Chiang Mai University, Thailand

• Graham Taylor, MD - Imperial College, United Kingdom

• Claire Thorne, BA, MSc, PhD - University College London, United Kingdom

• Marissa Vicari - International AIDS Society, Switzerland

• Rachel Vreeman, MD, MS - Icahn School of Medicine at Mount Sinai, United States

The members of Scientific Committee are hand-picked by the Organizing Committee and the conference secretariat based on their significant contributions and commitment to the field. They assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.

The 12th International Workshop on HIV Pediatrics is supported by the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under Award Number R13HD103495.